Sinovac Reports Results of Influenza Study

China’s Sinovac Biotech has completed a Phase II trial of its H5N1 whole viron inactivated vaccine for pandemic flu.

The 402-patient, stratified, randomized, double-blind trial assessed the safety and immunogenicity of the vaccine and was conducted by the Beijing Centers for Disease Control and Prevention.

The preliminary results suggest that each of the dosages administered — 5, 10 and 15 micrograms — can induce varying degrees of immune response, Sinovac said.

The company received approval from the China State Food and Drug Administration in April to conduct Phase Ib and II trials of the H5N1 whole viron vaccine and Phase I and Phase II trials of the H5N1 split vaccine.